Cubist Systematic Strategies LLC Makes New $3.91 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Cubist Systematic Strategies LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 154,512 shares of the biopharmaceutical company's stock, valued at approximately $3,905,000. Cubist Systematic Strategies LLC owned approximately 0.23% of Celldex Therapeutics at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its position in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth about $81,000. KBC Group NV boosted its stake in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth about $121,000.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX traded up $0.83 during mid-day trading on Thursday, hitting $19.77. The stock had a trading volume of 254,372 shares, compared to its average volume of 889,463. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -7.71 and a beta of 1.39. The company's 50 day simple moving average is $18.90 and its 200 day simple moving average is $22.70.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CLDX shares. Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. The Goldman Sachs Group reduced their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, UBS Group reduced their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Celldex Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.